Prachi is a London-based journalist with extensive experience in the aviation industry. She has worked for several leading industry publications, covering a broad range of topics. Her expertise lies ...
Al Horford is officially bouncing out of Brookline, putting his home in the affluent Boston suburb on the market following a ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The transactions include upfront ...
In its largest acquisition to date, Incyte Inc. snagged rights to phase III-stage VGA-039, a monoclonal antibody the firm said could offer a new standard of care in von Willebrand disease (VWD), in a ...
Incyte is acquiring Vega Therapeutics, a subsidiary of Star Therapeutics, for a bleeding disorder program that analysts say has “pipeline-in-a-product” potential. Incyte is adding a star to its ...
- Proposed acquisition to add VGA039, a novel investigational monoclonal antibody that targets Protein S in Phase 3 development for von Willebrand disease (VWD) - Star Therapeutics to receive $1.25 ...
Bill Meury, Incyte's chief executive. Incyte has agreed to buy Star Therapeutics subsidiary Vega Therapeutics for $1.25 billion upfront, adding a late-stage drug candidate for bleeding disorders.
Incyte INCY6.87%increase; up pointing triangle has agreed to buy Vega Therapeutics for up to $2 billion in a deal that expands the biopharmaceutical company’s hematology portfolio into bleeding ...
Incyte, a drugmaker with a heavy focus on blood diseases and cancers, plans to take control of an experimental medicine that could help control bleeding in a variety of disorders. Vega Therapeutics, a ...
June 8 (Reuters) - Incyte (INCY.O), opens new tab said on Monday it will buy Vega Therapeutics, a wholly owned subsidiary of privately held Star Therapeutics, in a deal worth up to $2 billion, ...
In its largest acquisition to date, Incyte Inc. snagged rights to phase III-stage VGA-039, a monoclonal antibody the firm said could offer a new standard of care in von Willebrand disease (VWD), in a ...
Deal terms for Vega include $1.25B upfront and up to $750M sales milestones, with expected close in Q3 2026 and a projected $1.25B R&D charge. VGA039 aims to improve hemostasis via Protein S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results